• Home
  •  / Taysha Gene Therapies

Taysha Gene Therapies

OverviewSuggest Edit

Taysha Gene Therapies is a biotechnology company. It develops treatments to eradicate monogenic diseases of the central nervous system (CNS).
TypePublic
Founded2020
HQDallas, TX, USMap
Websitetayshagtx.com
View Jobs (15)

Recent NewsAll News

Latest Updates

Job Openings15
Share Price (Jan 2022)$9.5
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Taysha Gene Therapies

RA Session II

RA Session II

President, Founder and CEO
Phillip B. Donenberg

Phillip B. Donenberg

Director
Kamran Alam

Kamran Alam

Chief Financial Officer
Sukumar Nagendran

Sukumar Nagendran

Director
Paul B. Manning

Paul B. Manning

Director
Suyash Prasad

Suyash Prasad

Chief Medical Officer and Head of Research and Development
Show more

Taysha Gene Therapies Office Locations

Taysha Gene Therapies has an office in Dallas
Dallas, TX, US (HQ)
2280 Inwood Rd
Show all (1)

Taysha Gene Therapies Financials and Metrics

Taysha Gene Therapies Revenue

USD

Net income (FY, 2020)

(60.0m)

EBIT (FY, 2020)

(43.0m)

Market capitalization (14-Jan-2022)

365.9m

Closing stock price (14-Jan-2022)

9.5

Cash (31-Dec-2020)

251.3m
Taysha Gene Therapies's current market capitalization is $365.9 m.
Annual
USDFY, 2019FY, 2020

General and administrative expense

128.0k11.1m

R&D expense

987.0k31.9m

Operating expense total

1.1m43.0m

EBIT

(1.1m)(43.0m)
Half Year
USDH1, 2020

General and administrative expense

1.0m

R&D expense

8.6m

Operating expense total

9.6m

EBIT

(9.6m)
Quarterly
USDQ3, 2020

General and administrative expense

4.0m

R&D expense

11.1m

Operating expense total

15.0m

EBIT

(15.0m)
show all
Annual
USDFY, 2019FY, 2020

Cash

251.3m

Prepaid Expenses

6.6m

Current Assets

15.0k257.9m

PP&E

287.0k
Quarterly
USDQ2, 2020Q3, 2020

Cash

11.2m278.6m

Prepaid Expenses

9.0k604.0k

Current Assets

11.3m279.2m

PP&E

19.0k28.0k
show all
Annual
USDFY, 2019FY, 2020

Net Income

(1.1m)(60.0m)

Depreciation and Amortization

9.0k

Accounts Payable

(6.6m)

Cash From Operating Activities

(30.7m)
Quarterly
USDQ2, 2020Q3, 2020

Net Income

(26.7m)(41.7m)

Depreciation and Amortization

3.0k

Accounts Payable

1.2m5.4m

Cash From Operating Activities

(4.2m)(10.9m)
show all
USDFY, 2019

Financial Leverage

-0.1 x
Show all financial metrics

Taysha Gene Therapies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Taysha Gene Therapies Online and Social Media Presence

Taysha Gene Therapies's Trends

Embed Graph

Taysha Gene Therapies News and Updates

March 11, 2021

Taysha Gene Therapies Announces Participation in Upcoming March Investor Healthcare Conferences

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announce…
March 09, 2021

Taysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Gene Payloads for an Aav Gene Therapy for the Treatment of Neurodevelopmental Disorders

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announce…
September 17, 2020

Taysha Gene Therapies sets IPO terms, could be valued at up to $690.4 million

Taysha Gene Therapies Inc. TSHA, +5.77% set terms Thursday for its initial public offering, as the Dallas-based company focused on treatments for central nervous system diseases looks to raise up to $131.6 million. The company is offering 6,578,970 shares in the IPO, which is expected to price betwe…
April 29, 2020

Taysha Gene Therapies Raises $30M in Seed Financing

Taysha Gene Therapies, a Dallas, TX-based developer of treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system (CNS), raised $30m in seed funding.

 Taysha Gene Therapies Frequently Asked Questions

  • When was Taysha Gene Therapies founded?

    Taysha Gene Therapies was founded in 2020.

  • Who are Taysha Gene Therapies key executives?

    Taysha Gene Therapies's key executives are RA Session II, Phillip B. Donenberg and Kamran Alam.

  • Who are Taysha Gene Therapies competitors?

    Competitors of Taysha Gene Therapies include Voyager Therapeutics, Lacerta Therapeutics and Passage Bio.

  • Where is Taysha Gene Therapies headquarters?

    Taysha Gene Therapies headquarters is located at 2280 Inwood Rd, Dallas.

  • Where are Taysha Gene Therapies offices?

    Taysha Gene Therapies has an office in Dallas.

  • How many offices does Taysha Gene Therapies have?

    Taysha Gene Therapies has 1 office.